View of การศึกษาเบื้องต้นผลของสารสกัดบอระเพ็ดพุงช้างต่อการทำงานของเกล็ดเลือดในหลอดทดลอง

(1)

∫∑§«“¡«‘®—¬

°“√»÷°…“‡∫◊ÈÕßµâπº≈¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß µàÕ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥„πÀ≈Õ¥∑¥≈Õß

**Õπ—≠≠“ π“«‘πª√–‡ √‘∞* Õ√æ‘≥ «ß»å «— ¥‘Ï°ÿ≈ ·≈– »√’Õ—¡æ√ ÀπŸ°≈—∫**

∫∑§—¥¬àÕ

∫Õ√–‡æÁ¥æÿß™â“ß‡ªìπæ◊™ ¡ÿπ‰æ√∑’Ë„™â„π°“√√—°…“‚√§¡–‡√Áß ‡∫“À«“π «—≥‚√§ ‚≈À‘µ®“ß ÀÕ∫À◊¥

·µà‰¡à¡’°“√»÷°…“∑“ß‡¿ —™«‘∑¬“∑’Ë‡°’Ë¬«°—∫√–∫∫‰À≈‡«’¬π‚≈À‘µ ®÷ß∑”°“√∑¥≈Õß‚¥¬„™â “√ °—¥∫Õ√–‡æÁ¥

æÿß™â“ß 1, 50, 150, 300 ·≈– 600 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ »÷°…“°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥∑’Ë‰¥â®“°æ≈“ ¡“

¢Õß§πª°µ‘ ‚¥¬„™â ADP (adenosine 5' diphosphate) 20 ‰¡‚§√‚¡≈“√å ‡ªìπ “√°√–µÿâπ°“√∑”ß“π¢Õß

‡°≈Á¥‡≈◊Õ¥ ´÷Ëß®–«—¥°“√‡°“–°≈ÿà¡°—π¢Õß‡°≈Á¥‡≈◊Õ¥‡ªìπ‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«¡“°∑’Ë ÿ¥ Õ—µ√“°“√

‡°“–°≈ÿà¡°—π¢Õß‡°≈Á¥‡≈◊Õ¥‡ªìπ‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«µàÕπ“∑’ ·≈–„™â luciferase ‡ªìπ “√«—¥°“√

À≈—Ëß¢Õß ATP ®“°°“√»÷°…“º≈¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ßµàÕ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥ æ∫«à“ “√ °—¥

∫Õ√–‡æÁ¥æÿß™â“ß∑’Ë§«“¡‡¢â¡¢âπ 50, 150, 300 ·≈– 600 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ ®–∑”„Àâ‡ªÕ√å‡´Áπµå· ß ºà“πÀ≈Õ¥·°â«¡“°∑’Ë ÿ¥ Õ—µ√“°“√‡ª≈’Ë¬π·ª≈ß¢Õß‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«µàÕπ“∑’ ·≈–°“√À≈—Ëß¢Õß ATP ≈¥≈ß · ¥ß«à“ “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß∑’Ë§«“¡‡¢â¡¢âπ¥—ß°≈à“«®–¬—∫¬—Èß°“√‡°“–°≈ÿà¡°—π¢Õß‡°≈Á¥

‡≈◊Õ¥ Õ—µ√“°“√‡°“–°≈ÿà¡°—π¢Õß‡°≈Á¥‡≈◊Õ¥™â“≈ß ·≈–°“√À≈—Ëß¢Õß ATP ≈¥≈ß ”À√—∫ “√ °—¥∫Õ√–‡æÁ¥

æÿß™â“ß∑’Ë§«“¡‡¢â¡¢âπ 1 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ ®–≈¥Õ—µ√“°“√‡ª≈’Ë¬π·ª≈ß¢Õß‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥

·°â«µàÕπ“∑’ ·µà‰¡à¡’º≈µàÕ‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«¡“°∑’Ë ÿ¥ ·≈–°“√À≈—Ëß ATP ¥—ßπ—Èπ “√ °—¥

∫Õ√–‡æÁ¥æÿß™â“ß 1 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ ®–∑”„ÀâÕ—µ√“°“√‡°“–°≈ÿà¡°—π¢Õß‡°≈Á¥‡≈◊Õ¥™â“≈ß ©–π—Èπ “√

°—¥∫Õ√–‡æÁ¥æÿß™â“ßÕ“®®–π”¡“„™â‡ªìπ·π«∑“ß„π°“√»÷°…“°≈‰°°“√¬—∫¬—Èß°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥ ·≈–

°“√π” ¡ÿπ‰æ√™π‘¥π’È¡“„™â„π°“√√—°…“‚√§∑’Ë‡°’Ë¬«°—∫√–∫∫‰À≈‡«’¬π‚≈À‘µµàÕ‰ª

§” ”§—≠: ∫Õ√–‡æÁ¥æÿß™â“ß °“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥

¿“§«‘™“‡¿ —™«‘∑¬“ §≥–·æ∑¬»“ µ√å ¡À“«‘∑¬“≈—¬»√’π§√‘π∑√«‘‚√≤

*ºŸâπ‘æπ∏åª√– “πß“π, e-mail: rung-aru@swu.ac.th

(2)

Preliminary Study of the Effects of Stephania venosa Extract on Platelet Functions in vitro

**Anunya Nawinprasert*, Orapin Wongsawatkul and Sriamporn Hnuklab**

ABSTRACT

Stephania venosa is Thai plant medicine that has been used for treatment of cancer, diabetes mellitus, tuberculosis, anemia and asthma. However, there is no evidence in pharmaco- logical study about cardiovascular system. In this study, the effects of S. venosa extract at 1, 50, 150, 300 and 600 µg/mL were examined in platelet function induced by ADP 20 µM from normal volunteer. Data were shown as platelet aggregation, the rate of platelet aggregation by measuring percentage of maximal changes in light transmission (LTmax), the rate of changes in light trans- mission (LTrate) and ATP release by using luciferase. The extract of S. venosa at 50, 150, 300 and 600 µg/mL caused the decreases in LTmax, LTrate and ATP release. It indicated that S. venosa extract inhibited platelet aggregation, decreased the rate of platelet aggregation and ATP release.

However, 1 µµg/mL of S. venosa extract decreased LTrate but not LTmax and ATP release.

This was shown that 1 µµg/mL of S. venosa extract reduced only the rate of platelet aggregation. Our findings suggested that S. venosa extract can be used to further investigate about mechanisms of these inhibitory effects and may be used for treatment of cardiovascular diseases.

Keywords: Stephania venosa, platelet function

Department of Pharmacology, Faculty of Medicine, Srinakharinwirot University

*Corresponding author, e-mail: rung-aru@swu.ac.th

(3)

∫∑π”

„πªí®®ÿ∫—πæ∫«à“‚√§∑’ËÕ“®∑”„Àâ‡°‘¥Õ—πµ√“¬∂÷ß·°à™’«‘µ ‡™àπ ‚√§À—«„® §«“¡¥—π‚≈À‘µ Ÿß ‡∫“À«“π ¡–‡√Áß

°“√µ‘¥‡™◊ÈÕ¢Õß√–∫∫µà“ßÊ „π√à“ß°“¬ Õ“®∑”„ÀâºŸâªÉ«¬∂÷ß·°à™’«‘µ‰¥â ‚√§À√◊Õ¿“«–∑’Ë‡°‘¥®“°°“√°√–µÿâπ°“√

∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥‡æ‘Ë¡¢÷Èπ ‰¥â·°à ‚√§À≈Õ¥‡≈◊Õ¥‚§‚√π“√’Ë (coronary artery disease) ‡∫“À«“π ¿“«–‰¢¡—π

„π‡≈◊Õ¥ Ÿß §«“¡¥—π‚≈À‘µ Ÿß ·≈–°“√ Ÿ∫∫ÿÀ√’Ë [1] ®”‡ªìπ®–µâÕß‰¥â√—∫¬“„π°“√√—°…“‡ªìπ‡«≈“π“π ∑”„Àâ‡°‘¥ƒ∑∏‘Ï

∑’Ë‰¡àæ÷ßª√– ß§å®“°°“√„™â¬“ ·≈–¬“∫“ß™π‘¥¡’√“§“·æß ¥—ßπ—Èπ ®÷ßæ‘®“√≥“∑’Ë®–π”æ◊™ ¡ÿπ‰æ√´÷Ëß‡æ“–ª≈Ÿ°‰¥â„π ª√–‡∑»‰∑¬¡“„™â„π°“√√—°…“‚√§µà“ßÊ ‡À≈à“π’È

∫Õ√–‡æÁ¥æÿß™â“ß‡ªìπ ¡ÿπ‰æ√‰∑¬Õ¬Ÿà„π«ß»å Menispermaceae [2] µ”√“‰∑¬·ºπ‚∫√“≥®–„™â‡ªìπ¬“

√—°…“∫“¥·º≈ ¥·≈–‡√◊ÈÕ√—ß Õ“°“√ª«¥‡¡◊ËÕ¬ ÀÕ∫À◊¥ Õ“À“√‰¡à¬àÕ¬ ≈¥√–¥—∫‰¢¡—π„π‡≈◊Õ¥ ‚√§‡∫“À«“πÀ√◊Õ

‚√§¡–‡√Áß à«π≈”µâπ®–„™â√–∫“¬≈¡„π∑âÕß à«π„∫„™â√—°…“∫“¥·º≈ ¥·≈–‡√◊ÈÕ√—ß à«π¢Õß¥Õ°®–„™â√—°…“‚√§

‡√◊ÈÕπ·≈–‡ªìπ¬“√–∫“¬ à«π‡∂“„™â¢—∫ª√–®”‡¥◊Õπ ¢—∫æ¬“∏‘„π≈”‰ â à«πÀ—«·≈–°â“π·°âª«¥‡¡◊ËÕ¬ à«π√“°∫”√ÿß

‡ âπª√– “∑·≈–√—°…“ÀÕ∫À◊¥ [3, 4] º≈®“°°“√»÷°…“«‘®—¬æ∫«à“∫Õ√–‡æÁ¥æÿß™â“ß®–„™â‡ªìπ¬“√–ß—∫ª«¥ √—°…“

ÀÕ∫À◊¥ ‚√§‡√◊ÈÕπ ·≈–«—≥‚√§‰¥â [5] ∑”≈“¬‡´≈≈å¡–‡√Áß‡µâ“π¡ [6] ·≈–¬—∫¬—Èß°“√‡®√‘≠‡µ‘∫‚µ¢Õß Plasmodium falciparum „πÀ≈Õ¥∑¥≈Õß [7] ·µà¬—ß‰¡à¡’¢âÕ¡Ÿ≈∑“ß‡¿ —™«‘∑¬“ ´÷Ëß»÷°…“‡°’Ë¬«°—∫√–∫∫‰À≈‡«’¬π‚≈À‘µ §≥–

ºŸâ«‘®—¬®÷ß π„®∑”°“√»÷°…“«‘®—¬º≈¢Õß ¡ÿπ‰æ√™π‘¥π’ÈµàÕ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥„πæ≈“ ¡à“¢Õß§πª°µ‘

«‘∏’°“√∑¥≈Õß

Õ“ “ ¡—§√

Õ“ “ ¡—§√™“¬ 4 §π À≠‘ß 16 §π Õ“¬ÿ√–À«à“ß 23-46 ªï ‰¡à¡’ª√–«—µ‘¡’‚√§ª√–®”µ—« ‰¡à‡§¬ Ÿ∫∫ÿÀ√’Ë À√◊Õ‰¥â√—∫¬“„¥Ê ¡“Õ¬à“ßπâÕ¬ 10 «—π°àÕπ‰¥â√—∫°“√‡®“–‡≈◊Õ¥ ·≈–Õ“ “ ¡—§√∑ÿ°§π‰¥â≈ß™◊ËÕ¬‘π¬Õ¡∑’Ë®–‡¢â“√à«¡

„π‚§√ß°“√«‘®—¬π’È

«— ¥ÿ·≈– “√‡§¡’

“√ sodium citrate, ADP (adenosine 5' diphosphate) ·≈– Luciferin/Luciferase (Sigma) “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß ‰¥â¡“®“°°“√π” à«πÀ—«¢Õß∫Õ√–‡æÁ¥æÿß™â“ß∑’Ëµ—¥‡ªìπ™‘Èπ‡≈Á°Ê ‰ªµ“°·Àâß ·≈â«π”¡“

30 °√—¡ ‡µ‘¡πÈ”°≈—Ëπ 1 ≈‘µ√ µâ¡„Àâ‡¥◊Õ¥‡ªìπ‡«≈“ 8 ™—Ë«‚¡ß °√Õß°“°ÕÕ° ∑‘Èß‰«â„Àâ‡¬Áπ≈ß∑’ËÕÿ≥À¿Ÿ¡‘ÀâÕß π”‰ª freeze dry ∑’ËÕÿ≥À¿Ÿ¡‘ -55 Õß»“‡´≈‡´’¬ §«“¡¥—π 0.1-0.04 ¡‘≈≈‘∫“√å ‡ªìπ‡«≈“ 72 ™—Ë«‚¡ß

°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥

Õ“ “ ¡—§√®–‰¥â√—∫°“√‡®“–‡≈◊Õ¥∑’Ë¢âÕæ—∫·¢π ·≈–„™â 3.2% sodium citrate ‡ªìπ “√ªÑÕß°—π°“√·¢Áßµ—«

¢Õß‡≈◊Õ¥ º ¡„πÕ—µ√“ à«π‡≈◊Õ¥: 3.2% sodium citrate ‡∑à“°—∫ 9: 1 π”µ—«Õ¬à“ß‡≈◊Õ¥ 100 ‰¡‚§√≈‘µ√ ‰ª

«—¥®”π«π‡¡Á¥‡≈◊Õ¥¢“« ‡¡Á¥‡≈◊Õ¥·¥ß Œ’‚¡‚°≈∫‘π Œ’¡“‚∑§√‘µ ·≈–‡°≈Á¥‡≈◊Õ¥‚¥¬„™â‡§√◊ËÕß Automatic Cell Counter ‡≈◊Õ¥∑’Ë‡À≈◊Õπ”‰ªªíòπ∑’Ë 400 xg ‡ªìπ‡«≈“ 10 π“∑’ ‚¥¬„™â‡§√◊ËÕß Mistral 2000 ®–‰¥â‡ªìπ Platelet Rich Plasma (PRP) π”‰ª„ à„πÀ≈Õ¥·°â«∑’Ë‡§≈◊Õ∫¥â«¬ silicone ª√‘¡“µ√ 250 ‰¡‚§√≈‘µ√ π” PRP ∑’Ë‡À≈◊Õ‰ªªíòπ

∑’Ë 2,900 xg ‡ªìπ‡«≈“ 10 π“∑’ ·≈â«π” à«π¢Õßæ≈“ ¡“´÷Ëß‡ªìπ Platelet Poor Plasma (PPP) ®”π«π 280

‰¡‚§√≈‘µ√ „ à„πÀ≈Õ¥·°â«∑’Ë‡§≈◊Õ∫ silicone ‡µ‘¡ “√ luciferin/luciferase („™â ”À√—∫«—¥ ATP) 0.5 ¡‘≈≈‘-

(4)

°√—¡µàÕπÈ”°≈—Ëπ∑’Ëª√“»®“°Õ‘ÕÕπ 20 ‰¡‚§√≈‘µ√ 0.9% ‚´‡¥’¬¡§≈Õ‰√¥å ®”π«π 5 ‰¡‚§√≈‘µ√ À√◊Õ “√ °—¥

∫Õ√–‡æÁ¥æÿß™â“ß 1, 50, 150, 300, 600 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ ≈ß„π PRP ·≈â«π” PRP π’È·≈– PPP Õÿàπ

„π‡§√◊ËÕß Chrono-Log Aggregometer Model 550 37 Õß»“‡´≈‡´’¬ ‡ªìπ‡«≈“ 3 π“∑’ À≈—ß®“°π—Èπªíòπ„π Õ—µ√“ 1,000 √Õ∫µàÕπ“∑’ ‡ªìπ‡«≈“ 1 π“∑’ „π‡§√◊ËÕß Chrono-Log Aggregometer ·≈â«‡µ‘¡ 20 ‰¡‚§√‚¡≈“√å ADP ®”π«π 5 ‰¡‚§√≈‘µ√ ≈ß„π PRP ∫—π∑÷°‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«¡“°∑’Ë ÿ¥ Õ—µ√“°“√‡ª≈’Ë¬π·ª≈ß

¢Õß‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â« ·≈–°“√À≈—Ëß¢Õß ATP ‡ªìπ‡«≈“ 4 π“∑’

°“√«‘‡§√“–Àå∑“ß ∂‘µ‘

º≈¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ßµàÕ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥®–§”π«≥‡ªìπ§à“‡©≈’Ë¬ ± §à“ à«π‡∫’Ë¬ß‡∫π

¡“µ√∞“π ·≈–«‘‡§√“–Àå¢âÕ¡Ÿ≈‚¥¬„™â Student paired t-test

º≈°“√∑¥≈Õß

Õ“ “ ¡—§√¡’®”π«π‡¡Á¥‡≈◊Õ¥¢“« ‡¡Á¥‡≈◊Õ¥·¥ß Œ’‚¡‚°≈∫‘π Œ’¡“‚∑§√‘µ ·≈–‡°≈Á¥‡≈◊Õ¥ª°µ‘ (µ“√“ß

∑’Ë 1) ‡¡◊ËÕ»÷°…“º≈¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ßµàÕ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥¢Õß§πª°µ‘„πÀ≈Õ¥∑¥≈Õß∑’Ë

°√–µÿâπ„Àâ¡’°“√‡°“–°≈ÿà¡°—π¢Õß‡°≈Á¥‡≈◊Õ¥‚¥¬„™â ADP 20 ‰¡‚§√‚¡≈“√å æ∫«à“ “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß 50, 150, 300 ·≈– 600 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ ®–∑”„Àâ‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«¡“°∑’Ë ÿ¥≈¥≈ß (√Ÿª∑’Ë 1) µ“√“ß∑’Ë 1 · ¥ß®”π«πÀ√◊Õ§à“¢ÕßÕß§åª√–°Õ∫„π‡≈◊Õ¥¢ÕßÕ“ “ ¡—§√

®”π«πÀ√◊Õ§à“¢ÕßÕß§åª√–°Õ∫„π‡≈◊Õ¥ ™“¬ (4 §π) À≠‘ß (16 §π)

‡¡Á¥‡≈◊Õ¥¢“« (x 10³ ‡´≈≈å/‰¡‚§√≈‘µ√) 6 ± 1 6 ± 1

‡¡Á¥‡≈◊Õ¥·¥ß (x 10⁶ ‡´≈≈å/‰¡‚§√≈‘µ√) 5 ± 0 4 ± 0 Œ’‚¡‚°≈∫‘π (°√—¡µàÕ‡¥´‘≈‘µ√) 13.075 ± 1.473 12.197 ± 1.54

Œ’¡“‚∑§√‘µ (‡ªÕ√å‡´Áπµå) 37.55 ± 6.527 34.541 ± 1.888

‡°≈Á¥‡≈◊Õ¥ (x 10³ ‡´≈≈å/‰¡‚§√≈‘µ√) 248 ± 76 224 ± 35

Õ—µ√“°“√‡ª≈’Ë¬π·ª≈ß¢Õß‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«≈¥≈ß (√Ÿª∑’Ë 2) ·≈–°“√À≈—Ëß¢Õß ATP (√Ÿª∑’Ë 3) ®–≈¥≈ßÕ¬à“ß¡’π—¬ ”§—≠∑“ß ∂‘µ‘ ‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫°—∫ 0.9 % NaCl (p value < 0.05) ·µà “√ °—¥∫Õ√–‡æÁ¥

æÿß™â“ß∑’Ë 1 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ ®–≈¥‡©æ“–Õ—µ√“°“√‡ª≈’Ë¬π·ª≈ß¢Õß‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«Õ¬à“ß¡’

π—¬ ”§—≠∑“ß ∂‘µ‘ (p value < 0.05)

√ÿª·≈–«‘®“√≥åº≈°“√∑¥≈Õß

°“√»÷°…“º≈¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ßµàÕ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥„πÀ≈Õ¥∑¥≈Õß‚¥¬„™â‡§√◊ËÕß Aggregometer ·≈–°√–µÿâπ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥‚¥¬„™â ADP 20 ‰¡‚§√‚¡≈“√å ´÷Ëß‡ªìπ “√∑’Ë∑”„Àâ‡°≈Á¥

‡≈◊Õ¥‡°“–°≈ÿà¡°—π„π°√–∫«π°“√·¢Áßµ—«¢Õß‡≈◊Õ¥ ·≈–°“√‡°‘¥≈‘Ë¡‡≈◊Õ¥Õÿ¥µ—π„πÀ≈Õ¥‡≈◊Õ¥·¥ß [8, 9] ®“°°“√

(5)

√Ÿª∑’Ë 2 · ¥ßº≈¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ßµàÕÕ—µ√“°“√‡°“–°≈ÿà¡°—π¢Õß‡°≈Á¥‡≈◊Õ¥‡¡◊ËÕ°√–µÿâπ¥â«¬ ADP 20 ‰¡‚§√‚¡≈“√å §à“∑’Ë· ¥ß‡ªìπ§à“‡©≈’Ë¬¢ÕßÕ—µ√“°“√‡ª≈’Ë¬π·ª≈ß¢Õß‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«

¡“°∑’Ë ÿ¥ ± §à“ à«π‡∫’Ë¬ß‡∫π¡“µ√∞“π ®”π«πµ—«Õ¬à“ß 20 µ—«Õ¬à“ß ¬°‡«âπ§«“¡‡¢â¡¢âπ∑’Ë 1 ‰¡‚§√-

°√—¡µàÕ¡‘≈≈‘≈‘µ√¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß ¡’ 19 µ—«Õ¬à“ß

* · ¥ß§à“ p < 0.05 ‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫°—∫ 0.9% NaCl

§«“¡‡¢â¡¢âπ¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß (‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√)

√Ÿª∑’Ë 1 · ¥ßº≈¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ßµàÕ°“√‡°“–°≈ÿà¡°—π¢Õß‡°≈Á¥‡≈◊Õ¥‡¡◊ËÕ°√–µÿâπ¥â«¬ ADP 20

‰¡‚§√‚¡≈“√å §à“∑’Ë· ¥ß‡ªìπ§à“‡©≈’Ë¬‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«¡“°∑’Ë ÿ¥ ± §à“ à«π‡∫’Ë¬ß‡∫π¡“µ√-

∞“π ®”π«πµ—«Õ¬à“ß 20 µ—«Õ¬à“ß ¬°‡«âπ§«“¡‡¢â¡¢âπ∑’Ë 1 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ ¢Õß “√ °—¥

∫Õ√–‡æÁ¥æÿß™â“ß¡’ 19 µ—«Õ¬à“ß

*· ¥ß§à“ p < 0.05 ‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫°—∫ 0.9% NaCl

· ßºà“πÀ≈Õ¥·°â«¡“°∑’Ë ÿ¥ (‡ªÕ√å‡´Áπµå)

Õ—µ√“°“√‡ª≈’Ë¬π·ª≈ß¢Õß· ßºà“πÀ≈Õ¥·°â« (‡ªÕ√å‡´ÁπµåµàÕπ“∑’)

(6)

»÷°…“º≈¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß∑’Ë 50, 150, 300 ·≈– 600 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ æ∫«à“ “√ °—¥∑’Ë§«“¡

‡¢â¡¢âπµà“ßÊ ‡À≈à“π’È ®–∑”„Àâ‡ªÕ√å‡´Áπµå· ßºà“πÀ≈Õ¥·°â«¡“°∑’Ë ÿ¥·≈–°“√À≈—Ëß ATP ≈¥≈ß à«π “√ °—¥

∫Õ√–‡æÁ¥æÿß™â“ß∑’Ë 1, 50, 150, 300 ·≈– 600 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ ®–≈¥Õ—µ√“°“√‡ª≈’Ë¬π·ª≈ß¢Õß‡ªÕ√å-

‡´Áπµå· ßºà“πÀ≈Õ¥·°â«

®“°º≈°“√∑¥≈Õß· ¥ß«à“ “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß∑’Ë 50, 150, 300 ·≈– 600 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√

®–¬—∫¬—Èß°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥ ‡¡◊ËÕ°√–µÿâπ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥‚¥¬„™â ADP 20 ‰¡‚§√‚¡≈“√å ·µà “√

∑¥≈Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß∑’Ë¡’ƒ∑∏‘Ï¬—∫¬—Èß°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥ Õ“®®–‡°’Ë¬«¢âÕß°—∫µ—«√—∫ P2T, P2X

À√◊Õ P2Y [10-14] ‡π◊ËÕß®“°¡’°“√°√–µÿâπ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥¥â«¬ ADP

√ÿªº≈°“√∑¥≈Õß

®“°°“√π”‡≈◊Õ¥¢Õß§πª°µ‘¡“ªíòπ·¬°æ≈“ ¡“‡æ◊ËÕ»÷°…“°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥·≈–º≈¢Õß “√ °—¥

∫Õ√–‡æÁ¥æÿß™â“ßµàÕ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥ ‚¥¬°√–µÿâπ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥¥â«¬ ADP 20 ‰¡‚§√‚¡≈“√å æ∫«à“ “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß∑’Ë§«“¡‡¢â¡¢âπ 1 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√ ®–¬—∫¬—Èß°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥‰¥â

®–¬—∫¬—Èß°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥‰¥â∑—Èß°“√‡°“–°≈ÿà¡°—π Õ—µ√“°“√‡°“–°≈ÿà¡°—π ·≈–°“√À≈—Ëß ATP ´÷ËßÕ“®

®–¡’°“√¬—∫¬—Èß°“√∑”ß“π¢Õßµ—«√—∫ P2T, P2X À√◊Õ P2Y®“°º≈°“√∑¥≈Õßπ’È®–π”‰ª Ÿà°“√»÷°…“°≈‰°°“√ÕÕ°

√Ÿª∑’Ë 3 · ¥ßº≈¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ßµàÕ°“√À≈—Ëß ATP ‡¡◊ËÕ°√–µÿâπ°“√∑”ß“π¢Õß‡°≈Á¥‡≈◊Õ¥¥â«¬ ADP 20 ‰¡‚§√‚¡≈“√å §à“∑’Ë· ¥ß‡ªìπ§à“‡©≈’Ë¬¢Õß°“√À≈—Ëß ATP ± §à“ à«π‡∫’Ë¬ß‡∫π¡“µ√∞“π ®”π«πµ—«Õ¬à“ß 10 µ—«Õ¬à“ß ¬°‡«âπ§«“¡‡¢â¡¢âπ∑’Ë 1 ‰¡‚§√°√—¡µàÕ¡‘≈≈‘≈‘µ√¢Õß “√ °—¥∫Õ√–‡æÁ¥æÿß™â“ß ¡’ 9 µ—«Õ¬à“ß

* · ¥ß§à“ p < 0.05 ‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫°—∫ 0.9% NaCl

°“√À≈—Ëß ATP

(7)

ƒ∑∏‘Ï·≈–°“√π” ¡ÿπ‰æ√™π‘¥π’È‰ª„™â„π°“√√—°…“‚√§∑’Ë‡°’Ë¬«¢âÕß°—∫√–∫∫‰À≈‡«’¬π‚≈À‘µµàÕ‰ª

°‘µµ‘°√√¡ª√–°“»

§≥–ºŸâ«‘®—¬¢Õ¢Õ∫§ÿ≥§≥–°√√¡°“√¢Õß ¡»« ∑’Ë°√ÿ≥“„Àâ∑ÿπÕÿ¥Àπÿπ°“√«‘®—¬®“°‡ß‘π°Õß∑ÿπæ—≤π“

¡À“«‘∑¬“≈—¬ ¡À“«‘∑¬“≈—¬»√’π§√‘π∑√«‘‚√≤

‡Õ° “√Õâ“ßÕ‘ß

1. Willoughby, S., Holmes, A. and Loscalzo, J. 2002. Platelets and Cardiovascular Disease. European Journal of Cardiovascular Nursing 1: 273-288.

2. ‡µÁ¡ ¡‘µ‘π—π∑πå. 2544. ™◊ËÕæ√√≥‰¡â·Ààßª√–‡∑»‰∑¬. °√ÿß‡∑æœ. À®°.øíππ’Ëæ—∫≈‘™™‘Ëß. Àπâ“ 496-497.

3. Forman, L. L. 1991. Menispermaceae. Flora of Thailand. 5(3): 300-365.

4. ÿπ∑√’ ‘ßÀ∫ÿµ√“. 2540. √√æ§ÿ≥ ¡ÿπ‰æ√ 200 ™π‘¥. °√ÿß‡∑æœ. ‚√ßæ‘¡æå¥Õ°‡∫’È¬. Àπâ“ 167.

5. Kozuka, M., Miyaji, K., Sawada, T. and Tomita, M. 1985. A Major Alkaloid of the Leaves and Stems of Stephania rotunda. J. Nat. Prod. 48: 341-342.

6. Keawpradub, N., Itharat, A., Tantikarnkul, A., Rugleng, S. and Inruspong, P. 2001. Cytotoxic Alkaloids from the Tuber of Stephania venosa. Songklanakarin J. Sci. Technol. 23: 225-234.

7. Likhitwitayawuid, K., Dej-adisai, S., Jongbunprasert, V., Krungkrai, J. 1999. Antimalarials from Stephania venosa, Prismatomeris sessiliflora, Diospyros montana and Murraya siamensis. Planta Med. 65: 754-756.

8. Hellem, A. J. 1960. The Adhesiveness of Human Blood Platelets in vitro. Scand. J. Clin. Lab.

Invest. 12: 1.

9. Gachet, C., Hechler, B., Leon, C., Vial, C., Leray, C., Ohlmann, P. and Cazenave, J. P. 1997.

Activation of ADP Receptors and Platelet Function. Thromb. Haemost. 78: 271.

10. Sage, S. O., Yamoah, E. H. and Heemskerk, J. W. 2000. The Roles of P2X (1) and P2T (AC) Receptors in ADP-Evoked Calcium Signalling in Human Platelets. Cell Calcium 28: 119-126.

11. Hoylaerts, M. F., Oury, C., Toth-Zsamboki, E. and Vermylen, J. 2000. ADP Receptors in Platelet Activation and Aggregation. Platelets 11: 307-309.

12. Hollopeter, G., Jantzen, H. M., Vincent, D., England, L., Ramakrishnan, V., Yang, R. B., Nurden, P., Nurden, A., Julius, D., and Conley, P. B. 2001. Identification of the Platelet ADP Receptor Targeted by Antithrombotic Drugs. Nature 409: 202-207.

13. Takasaki, J., Kamohara, M., Saito, T., Matsumoto, M., Matsumoto, S., Ohishi, T., Soga, T., Matsushime, H. and Furuichi, K. 2001. Molecular Cloning of the Platelet P2T(AC) ADP Receptor: Pharmacological Comparison with Another ADP Receptor, the P2Y(1) Receptor.

Mol. Pharmacol. 60: 432-439.

14. Kunapuli, S. P., Dorsam, R. T., Kim, S. and Quinton, T. M. 2003. Platelet Purinergic Receptors.

Curr. Opi. Pharmacol. 3: 175-180.

‰¥â√—∫∫∑§«“¡«—π∑’Ë 16 ¡’π“§¡ 2549

¬Õ¡√—∫µ’æ‘¡æå«—π∑’Ë 30 ‡¡…“¬π 2549